Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit

Christy Maggiore, Jose A. Vazquez, David J. Guervil, Ananthakrishnan Ramani, Alena Jandourek, Phillip Cole, H. David Friedland

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Clinical Assessment Program and Tefaro® Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and February 2013, from 398 evaluable patients receiving treatment at 33 sites in the USA. This manuscript presents data collected from patients with CABP who received care in an intensive care unit (ICU) or in general medical wards (35% and 64% of evaluable patients, respectively). The majority of ICU and general medical ward patients had underlying comorbidities (78% and 74%, respectively), with structural lung disease being the most common (42% in the ICU and 40% in general medical wards). Patients admitted to the ICU had a longer duration of stay, a longer duration of symptoms before treatment, and a longer duration of ceftaroline fosamil therapy than did general medical ward patients. Most patients treated in the ICU and in general medical wards were given ceftaroline fosamil as second-line therapy (87% and 80%, respectively). The overall rate of clinical success for patients treated with ceftaroline fosamil was 68% in the ICU and 85% in the general medical wards. Clinical success for patients receiving ceftaroline fosamil as a second-line agent was 84% in the ICU and 86% in general medical wards. These fndings indicate that ceftaroline fosamil is a viable treatment option for CABP, both in the ICU and in general medical wards.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume11
DOIs
StatePublished - Apr 2 2015

Fingerprint

Bacterial Pneumonia
Intensive care units
Patients' Rooms
Intensive Care Units
community
Therapeutics
Skin
duration of stay
Pulmonary diseases
PPI-0903
comorbidity
Lung Diseases
Multicenter Studies
Registries
Comorbidity
utilization
Disease

Keywords

  • CAPTURE
  • Registry

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit. / Maggiore, Christy; Vazquez, Jose A.; Guervil, David J.; Ramani, Ananthakrishnan; Jandourek, Alena; Cole, Phillip; Friedland, H. David.

In: Therapeutics and Clinical Risk Management, Vol. 11, 02.04.2015, p. 557-563.

Research output: Contribution to journalArticle

Maggiore, Christy ; Vazquez, Jose A. ; Guervil, David J. ; Ramani, Ananthakrishnan ; Jandourek, Alena ; Cole, Phillip ; Friedland, H. David. / Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit. In: Therapeutics and Clinical Risk Management. 2015 ; Vol. 11. pp. 557-563.
@article{ef657e8128a54bd59e12853814ad8f03,
title = "Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit",
abstract = "The Clinical Assessment Program and Tefaro{\circledR} Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and February 2013, from 398 evaluable patients receiving treatment at 33 sites in the USA. This manuscript presents data collected from patients with CABP who received care in an intensive care unit (ICU) or in general medical wards (35{\%} and 64{\%} of evaluable patients, respectively). The majority of ICU and general medical ward patients had underlying comorbidities (78{\%} and 74{\%}, respectively), with structural lung disease being the most common (42{\%} in the ICU and 40{\%} in general medical wards). Patients admitted to the ICU had a longer duration of stay, a longer duration of symptoms before treatment, and a longer duration of ceftaroline fosamil therapy than did general medical ward patients. Most patients treated in the ICU and in general medical wards were given ceftaroline fosamil as second-line therapy (87{\%} and 80{\%}, respectively). The overall rate of clinical success for patients treated with ceftaroline fosamil was 68{\%} in the ICU and 85{\%} in the general medical wards. Clinical success for patients receiving ceftaroline fosamil as a second-line agent was 84{\%} in the ICU and 86{\%} in general medical wards. These fndings indicate that ceftaroline fosamil is a viable treatment option for CABP, both in the ICU and in general medical wards.",
keywords = "CAPTURE, Registry",
author = "Christy Maggiore and Vazquez, {Jose A.} and Guervil, {David J.} and Ananthakrishnan Ramani and Alena Jandourek and Phillip Cole and Friedland, {H. David}",
year = "2015",
month = "4",
day = "2",
doi = "10.2147/TCRM.S75191",
language = "English (US)",
volume = "11",
pages = "557--563",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit

AU - Maggiore, Christy

AU - Vazquez, Jose A.

AU - Guervil, David J.

AU - Ramani, Ananthakrishnan

AU - Jandourek, Alena

AU - Cole, Phillip

AU - Friedland, H. David

PY - 2015/4/2

Y1 - 2015/4/2

N2 - The Clinical Assessment Program and Tefaro® Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and February 2013, from 398 evaluable patients receiving treatment at 33 sites in the USA. This manuscript presents data collected from patients with CABP who received care in an intensive care unit (ICU) or in general medical wards (35% and 64% of evaluable patients, respectively). The majority of ICU and general medical ward patients had underlying comorbidities (78% and 74%, respectively), with structural lung disease being the most common (42% in the ICU and 40% in general medical wards). Patients admitted to the ICU had a longer duration of stay, a longer duration of symptoms before treatment, and a longer duration of ceftaroline fosamil therapy than did general medical ward patients. Most patients treated in the ICU and in general medical wards were given ceftaroline fosamil as second-line therapy (87% and 80%, respectively). The overall rate of clinical success for patients treated with ceftaroline fosamil was 68% in the ICU and 85% in the general medical wards. Clinical success for patients receiving ceftaroline fosamil as a second-line agent was 84% in the ICU and 86% in general medical wards. These fndings indicate that ceftaroline fosamil is a viable treatment option for CABP, both in the ICU and in general medical wards.

AB - The Clinical Assessment Program and Tefaro® Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and February 2013, from 398 evaluable patients receiving treatment at 33 sites in the USA. This manuscript presents data collected from patients with CABP who received care in an intensive care unit (ICU) or in general medical wards (35% and 64% of evaluable patients, respectively). The majority of ICU and general medical ward patients had underlying comorbidities (78% and 74%, respectively), with structural lung disease being the most common (42% in the ICU and 40% in general medical wards). Patients admitted to the ICU had a longer duration of stay, a longer duration of symptoms before treatment, and a longer duration of ceftaroline fosamil therapy than did general medical ward patients. Most patients treated in the ICU and in general medical wards were given ceftaroline fosamil as second-line therapy (87% and 80%, respectively). The overall rate of clinical success for patients treated with ceftaroline fosamil was 68% in the ICU and 85% in the general medical wards. Clinical success for patients receiving ceftaroline fosamil as a second-line agent was 84% in the ICU and 86% in general medical wards. These fndings indicate that ceftaroline fosamil is a viable treatment option for CABP, both in the ICU and in general medical wards.

KW - CAPTURE

KW - Registry

UR - http://www.scopus.com/inward/record.url?scp=84928169546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928169546&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S75191

DO - 10.2147/TCRM.S75191

M3 - Article

AN - SCOPUS:84928169546

VL - 11

SP - 557

EP - 563

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -